Company Overview of Drais Pharmaceuticals, Inc.
Drais Pharmaceuticals, Inc., a drug development company, focuses on early and mid-stage clinical development through proof of concept. The company’s pipeline products include ASP7035, a small molecule selective vasopressin 2 receptor agonist for the treatment of nocturia; and ASP7147, a small molecule bombesin-2 receptor antagonist to improve symptoms in patients with diarrhea-predominant irritable bowel syndrome. Drais Pharmaceuticals, Inc. was founded in 2007 and is based in Bridgewater, New Jersey.
520 US Highway 22
Bridgewater, NJ 08807
Founded in 2007
Key Executives for Drais Pharmaceuticals, Inc.
Similar Private Companies By Industry
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
|7 Oaks Pharmaceutical Corp.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
To contact Drais Pharmaceuticals, Inc., please visit www.draispharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.